Guanfacine kinetics in patients with hypertension

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Pharmacokinetics

Background:

• Understanding drug behavior in the body is crucial for effective hypertension management.
• Guanfacine is a medication used to treat hypertension.
• Detailed pharmacokinetic data informs optimal dosing strategies.

Purpose of the Study:

• To investigate the pharmacokinetic profile of guanfacine after single and multiple oral doses in hypertensive patients.
• To assess the linearity and bioavailability of guanfacine at different therapeutic doses.
• To evaluate a method for predicting steady-state plasma concentrations during chronic guanfacine administration.

Main Methods:

• Single and multiple oral dose pharmacokinetic studies in 19 hypertensive patients.
• Plasma concentration-time data analyzed using a two-compartment open model with first-order absorption.
• Comparison of pharmacokinetic parameters (e.g., t 1/2, AUC) between 2 mg and 4 mg doses.
• Validation of a predictive method using four blood samples collected at specific time points post-dose.

Main Results:

• Guanfacine exhibited rapid absorption (t 1/2 ≈ 0.53 hr) and biphasic elimination (t 1/2 fast ≈ 2 hr, t 1/2 slow ≈ 19 hr).
• Bioavailability was equal and kinetics were linear between 2 mg and 4 mg doses, with low interindividual variation in peak plasma levels.
• Steady-state plasma levels in multiple-dosing studies closely matched predicted values and were dose-proportional.
• The percentage of drug in red blood cells remained constant at therapeutic levels.

Conclusions:

• Guanfacine demonstrates linear pharmacokinetics and predictable bioavailability in hypertensive patients.
• A simplified sampling method allows for reliable prediction of effective steady-state guanfacine levels during chronic treatment.
• These findings support the use of guanfacine for hypertension management with optimized dosing regimens.